The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

The HHS secretary’s plans would create a new Administration for a Healthy America (AHA) subagency and slash the department’s workforce by 25%, including 3,500 full-time positions at the FDA.

Division of HIV Prevention tracks outbreaks, provides education and establishes guidelines for the United States and the ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

During last year’s enrollment period, millions of Medicare beneficiaries reviewed their coverage options and selected new Medicare plans for the 2025 calendar year due to changes including the plans ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.